Accord Backed In EU For Trastuzumab And Apixaban
Part Of May Meeting of EMA’s CHMP
Accord Healthcare is looking to breaking into the crowded market for biosimilar trastuzumab in the EU, after partner Henlius’ application was backed by the EMA’s CHMP. Meanwhile, a recommendation for a generic to the Eliquis anticoagulant was also forthcoming from the committee.
You may also be interested in...
Sandoz looks to be in line for an EU-wide approval for its trastuzumab biosimilar during 2023, with the backing of the EMA’s Committee for Medicinal Products for Human Use.
ANDA filers that went to trial over Bristol Myers Squibb and Pfizer’s Eliquis blockbuster face a seven-year wait to launch their generic products after the US Court of Appeals for the Federal Circuit upheld a lower court decision.
Accord has launched its first monoclonal antibody biosimilar and fourth biosimilar overall, introducing in the UK the Zercepac version of trastuzumab developed by China’s Shanghai Henlius Biotech.